Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily Dialogue, Mid-Day, 9/14/11, pessimism deepens as confidence falls further

The 6 W’s: Who, what, where, when, why and what of it…

 

Mid-Day: The NASDAQ is UP +2081 (+0.81%) to 2,552.96. The Dow is UP +37.20 (+0.33%) to 11,143.05.  A more balanced day … for it has been exhausting watching this maket …

 

Mid-Day Movers:  Aastrom (ASTM), Athersys (NASDAQ:ATHX), BioTime (AMEX: BTX), Cytori (NASDAQ:CYTX), Dendreon (NASDAQ:DNDN), FibroCell (OTC BB: FCSC),  International Stem Cell (OTC BB: ISCO), Neuralstem (AMEX: CUR), ThermoGenesis (NASDAQ:KOOL) and Tengion (TNGN) …

 

What’s new in the regenerative medicine/stem cell market …

VistaGen Therapeutics Update:  OTCBB: VSTA has obtained more than $41M from various strategic collaborations, investments and grant awards. VSTA is using stem cell technology platform, Human Clinical Trials in a Test Tube(NYSE:TM), for both drug rescue and cell therapy. Its CNS drug development efforts are currently focused on clinical studies of AV-101 for neuropathic pain. Test Tube(TM) platform is based on a combination of proprietary and exclusively licensed pluripotent stem cell technologies. VSTA has leveraged its Human Clinical Trials in a Test Tube(TM) platform to produce mature human heart cells from pluripotent stem cells. Using mature, functional human heart cells, VSTA has developed CardioSafe 3D(TM), its initial three-dimensional, stem cell technology-based bioassay system. VistaGen believes CardioSafe 3D(TM) is capable of predicting many of the in vivo cardiac effects, both toxic and non-toxic, of small molecule drug candidates before they are tested in humans. The bottom line, VSTA’s goal is to use CardioSafe 3D(TM) to generate and monetize a pipeline of small molecule drug rescue variants through drug rescue collaborations focused on heart toxicity.  VSTA plans to expand the drug rescue capabilities of its Human Clinical Trials in a Test Tube(TM) platform by developing a second bioassay system, LiverSafe 3D(TM), using mature human liver cells produced from pluripotent stem cells to predict liver toxicity and drug metabolism. VistaGen plans to begin its 2nd P1b CNS clinical study of AV-101 for treatment of neuropathic pain before the end of 2011. To date, VSTA has been awarded over $8.5M from the NIH for development of AV-101. Hope, wing and a prayer company!

 

Mutant Protein May Improve Breast Tumors’ Response to Cancer Drugs, University of Texas MD Anderson Cancer Center Study:  Gene therapy delivered directly to a particularly stubborn type of breast cancer cell causes the cells to self-destruct, lowers chance of recurrence and helps increase the effectiveness of some types of chemotherapy, researchers at The University of Texas MD Anderson Cancer Center reported in the Sept. 13 edition of Cancer Cell. In cellular and mouse studies, scientists found the gene mutation BikDD significantly reduced treatment-resistant breast-cancer initiating cells (BCICs), also known as breast cancer stem cells, by blocking the activity of three proteins in the Bcl-2 family. The bottom line, this genetic approach increased the benefits of lapatinib, one of the most common chemotherapy drugs for breast cancer.

 

Pluristem Therapeutics forms bearish “Top Triangle” chart pattern: A “Top Triangle” chart pattern has formed on PSTI.  The pattern formed over 31 days which is roughly the period of time in which the target price range may be achieved. PSTI has a current resistance price of 2.62. No support level has been found. A Top Triangle/Wedge is considered a bearish signal, indicating a possible reversal of the current uptrend to a new downtrend. The pattern is formed during an uptrend and shows 2 trend lines converging. The technical event occurs when the price breaks downward out of the Triangle/Wedge formation and closes below the lower trend line; thereby confirming the pattern. This bearish pattern can be seen on the following chart and was detected by Recognia’s proprietary pattern recognition technology. The bottom line, this bearish signal indicates that the price may fall from the close of 2.29 to the range of 1.10 – 1.40.